Skip to main content

Table 1 Demographics and baseline characteristics

From: Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

Characteristics

All Patients (N = 30)

Median age (range), years

63.0 (45.0–83.0)

Sex, n (%)

 Male

19 (63)

 Female

11 (37)

Race, n (%)

 White

27 (90)

 Black

2 (7)

 Unknown

1 (3)

Primary tumor type, n (%)

 Colorectal cancer

13 (43)

 Head and neck cancer

10 (33)

 Urothelial transitional cell carcinoma

4 (13)

 Non–small-cell lung cancer

2 (7)

 Melanoma

1 (3)

ECOG performance status, n (%)

 0

9 (30)

 1

19 (63)

 2

2 (7)

Prior lines of therapy, n (%)

 1

4 (13)

 2

3 (10)

  ≥ 3

23 (77)

  1. ECOG Eastern Cooperative Oncology Group